Interference of levamisole with inhibition of E-rosette formation by Hodgkin's disease and systemic lupus erythematosus cytotoxic sera.
A new system has been used to test the influence of levamisole on T-cell function. Evidence has been produced that prior exposure to the drug "protects" normal human peripheral blood lymphocytes from the inhibition that cytotoxic sera from patients with Hodgkin's disease and systemic lupus erythematosus exhibit on their E-rosette-forming capacity. Also, damage of this T-cell function already induced by Hodgkin's sera may be partially corrected.
D003602:Cytotoxicity, Immunologic; D006689:Hodgkin Disease / Q000276:immunology*; D006801:Humans; D007978:Levamisole / Q000494:pharmacology*; D008180:Lupus Erythematosus, Systemic / Q000276:immunology*; D012397:Rosette Formation
D007978:Levamisole